Single injection of triamcinolone versus three repeated injections of bevacizumab for treatment of diabetic macular edema

International Ophthalmology

Volumn 33, Issue 4, 2013, Pages 375-380

  Taş, Mehmet ^a   Öner, Veysi ^b   Alakuş, Mehmet Fuat ^c   Türkcü, Fatih Mehmet ^d   Işcan, Yalçin ^c   Yüksel, Kemal ^e  

^a MALATYA STATE HOSPITAL   (Turkey)

^b RECEP TAYYIP ERDOGAN UNIVERSITY   (Turkey)

^c Batman Region State Hospital   (Turkey)

^d DICLE UNIVERSITY   (Turkey)

^e Beyoglu Eye Education and Research Hospital   (Turkey)

Author keywords

Bevacizumab; Diabetic macular edema; Intravitreal injection; Triamcinolone

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; TRIAMCINOLONE ACETONIDE; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; MONOCLONAL ANTIBODY;

ADULT; APPLANATION TONOMETER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; RETINAL THICKNESS; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SLIT LAMP; TONOMETRY; VISUAL ACUITY; AGED; DIABETIC RETINOPATHY; DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA;

AGED; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY;

EID: 84890179905     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-012-9709-z     Document Type: Article

References (36)

1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy IV. Diabetic macular edema. Ophthalmology 91:1464-1474 (Pubitemid 15197017)
2. Antcliff RJ, Marshall J (1999) The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14:223-232 (Pubitemid 30061165)
3. Fraser-Bell S, Kaines A, Hykin PG (2008) Update on treatments for diabetic macular edema. Curr Opin Ophthalmol 19:185-189 (Pubitemid 351535912)
4. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A (2006) Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26:999-1005 (Pubitemid 44973218)
5. Starita C, Patel M, Katz B, Adamis AP (2007) Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Dev Ophthalmol 39:122-148
6. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH, Solis-Vivanco A, Farah ME, Pan-American Collaborative Retina Study Group (2007) Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114:743-750 (Pubitemid 46483714)
7. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R (2008) Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 92:76-80
8. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, Caulin C, Gaudric A (2004) Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 111:218-224 (Pubitemid 38183217)
9. Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA (2005) Intravitreal injection versus sub-tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Investig Ophthalmol Vis Sci 46:3845-3849 (Pubitemid 44264695)
10. Faghihi H, Roohipoor R, Mohammadi SF, Hojat-Jalali K, Mirshahi A, Lashay A, Piri N, Faghihi Sh (2008) Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 18:941-948
11. Song JH, Lee JJ, Lee SJ (2011) Comparison of the short-term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema. Korean J Ophthalmol 25:156-160
12. Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, Soheilian M, Keshavarzi G, Mohebbi MR (2008) Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 246:483-489 (Pubitemid 351447960)
13. Rensch F, Spandau UH, Wickenhäuser A, Jonas JB (2010) Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide. Acta Ophthalmol 88:36-37
14. Kollias AN, Ulbig MW (2010) Diabetic retinopathy: early diagnosis and effective treatment. Dtsch Arztebl Int 107:75-84
15. Pegklidou K, Nicolaou I, Demopoulos VJ (2010) Nutritional overview on the management of type 2 diabetes and the prevention of its complications. Curr Diabetes Rev 6:400-409
16. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, Yeo KT (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445-450 (Pubitemid 24307211)
17. Funatsu H, Yamashita H, Nakamura S, Mimura T, Eguchi S, Noma H, Hori S (2006) Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 113:294-301 (Pubitemid 43170779)
18. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S (2009) Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 116:73-79
19. Roh MI, Kim HS, Song JH, Lim JB, Kwon OW (2009) Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology 116:80-86
20. Meleth AD, Agrón E, Chan CC, Reed GF, Arora K, Byrnes G, Csaky KG, Ferris FL 3rd, Chew EY (2005) Serum inflammatory markers in diabetic retinopathy. Investig Ophthalmol Vis Sci 46:4295-4301 (Pubitemid 44264635)
21. Adamis AP, Berman AJ (2008) Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 30:65-84
22. Zhang J, Gerhardinger C, Lorenzi M (2002) Early complement activation and decreased levels of glycosylphosphatidylinositolanchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes 51:3499-3504 (Pubitemid 35403456)
23. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP (2004) A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18:1450-1452 (Pubitemid 39561611)
24. Sutter FK, Simpson JM, Gilles MC (2004) Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 111:2044-2049 (Pubitemid 39446723)
25. Song JH, Lee JJ, Lee SJ (2011) Comparison of the short-term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema. Korean J Ophthalmol 25:156-160
26. Shahin MM, El-Lakkany RS (2010) A prospective, randomized comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab (avastin) in diffuse diabetic macular edema. Middle East Afr J Ophthalmol 17:250-253
27. Early treatment diabeticretinopathy study research group (1985) Photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 103:1796-1806
28. Early treatment Diabetic Retinopathy Study Research Group (1987) Technique for scatter and local photocoagulation treatment of diabetic retinopathy: early diabetic retinopathy study report No. 3. Int Ophthalmol Clin 27:254-264
29. Zafar A Zaidi, Jacob Mary K (1986) Effect of macular photocoagulation on visual acuity of Omani patients with clinically significant macular edema. Oman J Ophthalmol 2:62-66
30. Olk RJ (1986) Modified grid argon laser photocoagulation for diffuse diabetic macular edema. Ophthalmology 93:938-950 (Pubitemid 16046104)
31. Kang SW, Sa HS, Cho HY, Kim JI (2006) Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 124:653-658
32. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, Boyer D, Heier JS, Abraham P, Thach AB, Lit ES, Foster BS, Kruger E, Dugel P, Chang T, Das A, Ciulla TA, Pollack JS, Lim JI, Eliott D, Campochiaro PA, READ-2 Study Group (2010) Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 117:2146-2151
33. Solaiman KA, Diab MM, Abo-Elenin M (2010) Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema. Retina 30:1638-1645
34. Wang YS, Li X, Wang HY, Zhang ZF, Li MH, Su XN (2011) Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema. Chin Med J (Engl) 124:352-358
35. Folgosa MS, Messias A, Takata C, Costa RA, Scott IU, Jorge R (2010) Single intravitreal injection of triamcinolone combined with bevacizumab for the treatment of diffuse diabetic macular oedema refractory to grid photocoagulation. Acta Ophthalmol 88:297-298
36. Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, Soheilian M, Keshavarzi G, Mohebbi MR (2008) Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 246:483-489 (Pubitemid 351447960)